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Abstract 
Objective: The study evaluated the efficacy of phototherapy and 20% albumin infusion to reduce total serum biliru-
bin (TSB) in neonates with severe hyperbilirubinemia. The primary outcome was a reduction of TSB at the end of treat-
ment. The secondary outcomes were the need for exchange transfusion, inpatient mortality, neurological outcomes 
at discharge, and development outcomes at 12-months follow-up.
Results: One hundred and eighteen neonates were randomly assigned to phototherapy and 20% albumin (n = 59) 
and phototherapy and saline (n = 69). The median age at admission was 5 (interquartile range (IQR) 3–6) days, and the 
median gestation was 36 (IQR 36–38) weeks. No significant differences were found in the change in TSB (Mann–Whit-
ney U =609, p = 0.98) and rate of change in TSB per hour after treatment (Mann–Whitney U = 540, p = 0.39) between 
the two groups. There were no significant differences between the two groups in the proportion of participants who 
required exchange transfusion (χ2 (2) = 0.36, p = 0.546); repeat phototherapy (χ2 (2) = 2.37, p = 0.123); and those who 
died (χ2 (2) = 0.92, p = 0.337). Trial registration The trial was registered in the International Standardized Randomized 
Controlled Trial Number (ISRCTN); trial registration number ISRCTN89732754.
Keywords: Albumin, Saline, Neonates, Neonatal jaundice, Sub-Saharan Africa
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Neonatal jaundice (NNJ) is a common condition [1] 
and occurs when the breakdown of red blood cells is 
increased leading to an accumulation of bilirubin [2]. 
Globally, the overall incidence of NNJ is 9.9 (2.8–35.6) 
per 10,000 live births [1]. Africa has the highest num-
ber of children developing NNJ with an incidence of 
667.8 (603.4–738.5) per 10,000 live births [1]. In Kilifi 
County Hospital (KCH) Kenya, NNJ accounted for 24% 
of young infants’ mortality and was the primary diagno-
sis of 17% of over 1000 neonatal admissions during the 
first 60  days of life in 2003 [3]. Neonates may develop 
hyperbilirubinemia; total serum bilirubin (TSB) above 
the 95th percentile for that age (in hours). Phototherapy 
is the treatment of choice as it enhances the conversion 
of bilirubin into less toxic water-soluble photo-isomers 
[4] and is effective in the management of NNJ [5–9]. 
Severe unconjugated hyperbilirubinemia can cause neu-
rotoxicity that leads to brain damage in neonates [10] and 
is associated with irreversible neurodevelopmental, and 
neurological impairment [11–16].
The use of blue-light fluorescent tubes during photo-
therapy increases the need for maintenance fluid by 25% 
and additional intravenous fluid 1–1.5 times the main-
tenance fluid during intensive phototherapy [17]. The 
increased fluid, mainly dextrose water is needed to com-
pensate for fluid lost in the excretion of the water-soluble 
photo-products from bilirubin conversion. Lack of fluid 
may lead to dehydration in children undergoing photo-
therapy [18]. Moreover, adequate hydration and urine 
output improve the efficacy of phototherapy.
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Albumin infusion during phototherapy is reported to 
induce a rapid decline in unconjugated bilirubin dur-
ing phototherapy [19] since albumin binds to bilirubin. 
Hosono et  al. reported that 25% albumin infusion was 
more effective in reducing serum levels of unbound bili-
rubin during the first 6 and 24 h of treatment compared 
to phototherapy alone [20], but did not significantly 
reduce TSB levels at the end of treatment. In another 
study, it was reported that 10% albumin had a protective 
effect against bilirubin toxicity and may be useful in chil-
dren with severe hyperbilirubinemia [21]. Hosono et  al. 
further report that albumin infusion therapy is associated 
with better hearing outcomes at 6 months compared to 
standard care [22].
Despite the knowledge that albumin infusion during 
phototherapy may be useful, most of the evidence is from 
high-income countries, and less is known in sub-Saharan 
Africa (SSA) despite the high incidence of NNJ. The pre-
sent study evaluated the efficacy of phototherapy and 
20% albumin infusion versus standard care (photother-
apy and saline) in the reduction of bilirubin, exchange 
transfusion, inpatient mortality, neurological outcomes 
at discharge and development outcomes at 12-months.
Main text
Methods
Trial design
This is a randomized controlled trial of phototherapy 
and 20% albumin versus phototherapy and saline. The 
enrolled participants were randomized in a ratio of 1:1 to 
the albumin group and saline group.
Participants
The study was conducted at KCH from 2006 to 2011. All 
neonates admitted to KCH had a clinical assessment of 
NNJ. TSB was measured in neonates (0–30 days) admit-
ted to the KCH paediatric ward on the day of admission. 
Those with a TSB above 250 μmol/L were investigated 
to determine the cause of hyperbilirubinemia and were 
randomized to either phototherapy and 20% albumin 
or phototherapy and saline. The decision to start photo-
therapy was calculated based on the postnatal age, ges-
tational, and TSB levels at admission [23]. Phototherapy 
was initiated when TSB levels were from 85µ/mols/L/kg 
in babies below 2.5 kg (as a marker of prematurity). For 
sick neonates, treatment was started at 30µ/mols/L below 
the levels for the well baby. Participants were excluded 
from the study if they had a congenital abnormality, clini-
cal evidence of kernicterus, or obstructive jaundice.
Interventions
Neonates randomized to receive albumin were given one 
infusion of intravenous 20% albumin (1  g/kg) over 2  h. 
The neonates that were randomized to 1/5 (0.9%) normal 
saline sodium 154 mmol/L and chloride 154 mmol/L in 
10% dextrose received the same volume of fluid as those 
randomized to 20% albumin i.e. 5 ml/kg over a period of 
2 h. Hyperbilirubinemia was managed using Photolight, 
Model AS20 220–230 V with YZ20BT132/20W blue flu-
orescent tubes. All children were on a routine antibiotic 
cover (Benzyl Penicillin and Gentamicin) and mainte-
nance fluids (10% dextrose) [23]. Discharge from the hos-
pital occured only when the TSB was below phototherapy 
level (less than 85/μmol/l/kg) and after 24 h observation 
to check for rebound hyperbilirubinemia after photother-
apy was stopped.
Blood samples were taken for laboratory tests such as 
blood group determination and Coombs test (direct and 
indirect). Haemolytic causes were defined as mother-
baby blood incompatibility or Coombs test positive. TSB 
was measured at admission, at 2 h, 6 h, 24 h, 48 h post 
admission, and every 24 h thereafter until the child was 
discharged. Participants were withdrawn from photo-
therapy if there was a need for exchange transfusion, hos-
pital transfer, or death.
Study Outcomes
The primary study outcome was the reduction in TSB 
levels for the participants at the end of treatment. The 
secondary outcomes were the prevention of exchange 
transfusions during treatment, reduced inpatient mortal-
ity, neurological outcomes at discharge and developmen-
tal outcomes at 12-months.
Neurological and developmental assessment
A neurological assessments were performed using a 
clinical evaluation proforma designed for this study and 
assessed at discharge by a clinician blinded to the par-
ticipants’ treatment arm. The developmental assessments 
were taken at 12-months of age by trained assessors. 
The Kilifi Development Inventory (KDI) [24, 25] and the 
Developmental Milestones Checklist (DMC) [24, 25] 
were administered to evaluate psychomotor, language 
and social emotional function.
Sample size
The sample size was based on previous data from KCH in 
which 48% of children with severe hyperbilirubinaemia 
had neurological deficits [11]. To detect a 50% difference 
in neurological sequelae in the albumin-treated group, 
assuming 80% power, 70 participants in both arms were 
required giving a total of 140 participants. Adjustment 
for death and loss to follow up of 10% required 80 partici-
pants in each arm giving a total of 160 participants.
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Enrolment and randomization
The randomization was undertaken using card envelopes 
in blocks of 20. The random numbers were generated 
by the principal investigator and kept in serially num-
bered sealed opaque envelopes which were only opened 
after participants were enrolled in the study. However, 
due to the nature of this study, it was not possible for 
the investigators, assessors, clinicians, and parents to be 
blinded to the treatment arm once the participants were 
randomized.
Statistical analysis
Data were recorded on files, and double entered to a 
secure, Web-based REDCap database and analysed using 
STATA (version 15) [26]. Descriptive statistics such as 
frequencies, percentages, and median with respective 
interquartile ranges (IQR) were reported. Wilcoxon test 
was used to compare differences in TSB at admission and 
after treatment, while Mann–Whitney U test was used to 
compare the differences in change in TSB (the difference 
in TSB levels at the start and end of treatment) and rate of 
change per hour in TSB (the difference in the level of TSB 
at admission and at the end of treatment divided by the 
total number of hours taken on phototherapy) between 
the two treatments. Chi square test was used for com-
parisons of the proportion of participants who required 
exchange transfusion, repeat phototherapy, died, and 
participants who were discharged in the two treatments.
Results
One hundred and fifty-six participants were randomized 
in the study (75 assigned to 20% albumin while 76 
assigned to saline).
Demographic characteristics and proportion of partici-
pants who required exchange transfusion were analysed 
on 118 participants (59 in the 20% albumin arm and 69 in 
the saline arm).
Reduction in TSB levels in the two treatments was 
assessed on the 70 participants (34 in 20% albumin arm 
and 36 in the saline arm) whose data were available (see 
Additional file 1: Figure S1).
Participant characteristics
The baseline characteristics of participants enrolled in 
the study are given in Table 1. There were no significant 
differences in the demographic and baseline characteris-
tics between the participants who received phototherapy 
and albumin and phototherapy and saline at baseline. 
The median age at admission was 5 (IQR 3–6) days, the 
median gestation was 36 (IQR 36–38) weeks, and the 
median age for the mothers was 24 (IQR 19–28) years. 
Most of the participants (40.8%) had haemolytic causes 
of jaundice, 14.6% had non-haemolytic causes, 15.4% 
Table 1 Baseline characteristics participants
* Mann U Whitney
Characteristics 20% albumin + phototherapy (n = 59) Saline + phototherapy (n = 69) Test statistic
Age at admission (days)
 Median (IQR) 5 (3–6) 5 (4–6) P =0.574*
Estimated gestational weeks
 Median (IQR) 36 (36–37) 36 (36–38) –
Total serum bilirubin at admission
Median (IQR) 368 (303–456) 392 (316–510) P =0.331*
Mother’s age
 Median (IQR) 24 (19–29) 24 (20–27) P =0.331*
ABO incompatibility n
 Yes 28 25 χ2(2) = 1.85, P =0.173
 No 18 28
Non-haemolytic causes n
 Yes 10 9 χ2(2) = 0.21, P =0.646
 No 36 41
Both haemolytic and non-haemolytic n
 Yes 5 3 χ2(2) = 0.92, P =0.336
 No 54 66
Unknown causes
 Yes 13 18 χ2(2) = 0.28, P =0.594
 No 46 51
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had both haemolytic and non-haemolytic causes, while 
in 29.2% of the participants the causes of jaundice were 
unknown.
Reduction in bilirubin levels after treatment
The participants’ TSB levels after treatment were sig-
nificantly lower than TSB levels at admission in both the 
phototherapy and albumin (Z = 5.1, p < 0.00) and photo-
therapy and saline (Z = 5.2, p < 0.001) groups. There were 
no significant differences in the change in TSB (Mann–
Whitney U =609, p = 0.98) and rate of change in TSB per 
hour (Mann–Whitney U = 540, p = 0.39) between the 
two groups (Table 2).
Outcome after treatment
There were no significant differences (p > 0.05) in the 
proportion of participants who required exchange trans-
fusion (three in albumin group versus four in saline 
group), repeat phototherapy (two in albumin versus none 
in saline), those who died (six in albumin group versus 
eleven in saline group), and participants who were dis-
charged in the two treatments (Table 3).
Developmental outcomes at age 12‑months
There was no significant difference in the 20% album 
group and saline group in the scores for psychomo-
tor (M = 26.5, SD = 11.5, versus M = 20.1, SD = 13.8), 
t (55) = 1.9, p = 0.060; language (M = 7.3, SD = 4.3 ver-
sus M = 5.4, SD = 4.2), t (55) = 1.7, p = 0.090 and socio-
emotional function (M = 26.5, SD = 11.5 versus M = 25.7, 
SD = 11.8), t (55) = 0.9, p = 0.360.
Discussion
This randomized control trial investigated the efficacy 
of 20% albumin infusion in neonates with severe hyper-
bilirubinemia to enhance the binding of bilirubin in 
the plasma and consequently reduce TSB, the need for 
exchange transfusion, mortality during phototherapy, 
neurological impairment at discharge and improve devel-
opmental outcome at 12-months. The results reveal that 
albumin infusion lowers the TSB levels during treat-
ment, but there were no significant changes in TSB levels 
and rate of change in TSB per hour between the albu-
min infusion arm and the control group. Additionally, 
no significant differences were found in other outcomes 
including the need for repeat phototherapy, exchange 
transfusion, inpatient mortality, and developmental out-
comes at 12-months.
One of the reasons for the lack of effect of albumin 
infusion during phototherapy could be that the extrac-
tion of bilirubin from the tissues and its discharge into 
the blood depend on the phototherapy rather than 
additional albumin infused. These findings are similar 
to those reported by Hosono et  al. and Tsao and Vic-
tor who reported no significant reduction in TSB levels 
between the 25% albumin infusion group and control 
group. The second reason for lack of additional effect of 
albumin infusion during phototherapy is that albumin 
may lead to an increase in oncotic pressure, expanding 
plasma volume hence delay the excretion of bilirubin 
Table 2 Reduction in bilirubin levels at end of treatment in whom complete data were available
Descriptive statistics
SD standard deviation
* No significant differences in change of total serum bilirubin and rate of change in total serum reduction per hour between the two arms of the trial p > 0.05
Variable 20% albumin + phototherapy (n = 34) Saline + phototherapy 
(n = 36)
TSB at admission mean (SD) 387 (114) 370 (102)
TSB after phototherapy mean (SD) 191 (67) 188 (69)
Change in bilirubin*
 Median (IQR) 152 (101–248) 159 (101–230)
Rate of change (mg/dL/h)*
 Median (IQR) 2.16 (1.5–4.25) 1.91 (1.19–4.00)
Table 3 Outcome after treatment
20% albumin 
(n = 59)
Saline (n = 69) Test statistic
Type of discharge n (%)
 Alive 53 (89.8) 58 (84.1) χ2 (2) = 0.920, 
P = 0.337 Died 6 (10.2) 11 (15.9)
Repeat phototherapy n (%)
 Yes 2 (3.4) 0 (0.0) χ2 (2) = 2.376, 
P = 0.123 No 57 (96.6) 69 (100.0)
Exchange transfusion n (%)
 Yes 3 (4.4) 4 (6.8) χ2 (2) = 0.364, 
P = 0.546 No 55 (95.6) 66 (93.2)
Abnormal neuro-
logical functioning
– –
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from the body [20]. Third, the apparent ineffectiveness 
of albumin infusion may be due to oxidation of albumin 
during phototherapy. Oxidized albumin has a lesser 
affinity for bilirubin than albumin, thus promotes accu-
mulation of free bilirubin in the body [19].
In a recent Cochrane meta-analysis evaluating the role 
of fluid supplementation in the treatment of NNJ, the 
authors reported that there were no differences between 
the treatment and control groups in the TSB levels 4  h 
after phototherapy [27]. However, several studies have 
reported the effectiveness of albumin infusion during 
exchange transfusion [21, 28, 29]. These studies have 
indicated that the effect of albumin infusion is useful 
in the clearance of bilirubin from the neonates’ tissues 
which may not be cleared by exchange transfusion.
Limitations
There were a number of limitations to this trial. First, the 
trial was not a double-blind trial, although, the endpoints 
of bilirubin and the need for exchange transfusions are 
unlikely to be biased outcomes. Second, the plasma con-
centrations of unbound bilirubin were not consistently 
measured for participants in the treatment and control 
group, therefore, it is difficult to determine whether the 
infusion of albumin affected the unbound bilirubin or 
not. Additionally, the developmental assessments may 
not have detected more subtle impairments at 12 months 
of age that could impact functional abilities at a later age. 
Finally, the study had missing data on some participants 
hence they could not be included in this analysis. The 
missing data may potentially reduce the representative-
ness of the sample and introduced biasness in the estima-
tions of the outcomes of this study.
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